Show simple item record

dc.creatorSegura Ruiz, Álvaro
dc.creatorVillalta Arrieta, Mauren
dc.creatorHerrera Vega, María
dc.creatorLeón Montero, Guillermo
dc.creatorHarrison, Robert A.
dc.creatorDurfa, Nandul
dc.creatorNasidi, Abdulsalami
dc.creatorCalvete Chornet, Juan José
dc.creatorTheakston, R. David G.
dc.creatorWarrell, David A.
dc.creatorGutiérrez, José María
dc.date.accessioned2016-11-28T21:45:07Z
dc.date.available2016-11-28T21:45:07Z
dc.date.issued2010-02
dc.identifier.citationhttp://www.sciencedirect.com/science/article/pii/S0041010109004346es_ES
dc.identifier.issn0041-0101
dc.identifier.urihttp://hdl.handle.net/10669/29328
dc.description.abstractA preclinical assessment was performed on the neutralizing efficacy of a whole IgG polyspecific antivenom (EchiTAb-Plus-ICP®), designed for the treatment of snakebite envenomings in Nigeria. It was generated by immunizing horses with the venoms of Echis ocellatus, Bitis arietans and Naja nigricollis, the most medically important species in Nigeria. Antivenom was tested against the venoms of E. ocellatus, Echis leucogaster, Echis pyramidum leakeyi, B. arietans, Bitis gabonica, Bitis rhinoceros and Bitis nasicornis. The neutralization of the venom toxins responsible for the lethal, hemorrhagic, coagulant and local necrotizing activities was assessed, since these are the most significant effects that characterize envenoming by these species. Echis sp venoms exerted lethal, hemorrhagic, coagulant and necrotizing effects, whereas the Bitis sp venoms tested induced lethality, hemorrhage and necrosis, but were devoid of coagulant activity. The antivenom was effective in the neutralization of all effects tested in all venoms. Highest neutralization was achieved against the venoms of E. ocellatus and B. arietans, and the lowest neutralizing potency was against the venom of B. nasicornis, a species that has a low clinical relevance. It is concluded that EchiTAb-Plus-ICP®, whilst specifically designed for Nigeria, has a good preclinical neutralizing profile against homologous and heterologous viperid venoms from other sub-Saharan African locations. It therefore constitutes a promising therapeutic option for the treatment of snakebite envenoming in this region.es_ES
dc.description.sponsorshipUniversidad de Costa Rica/[741-A9-003]/UCR/Costa Ricaes_ES
dc.description.sponsorshipCRUSA-CSIC/2007CR0004//Españaes_ES
dc.language.isoen_USes_ES
dc.sourceToxicon; Volumen 55, Número 2-3. 2010es_ES
dc.subjectSub-Saharan Africaes_ES
dc.subjectSnakebitees_ES
dc.subjectEchis spes_ES
dc.subjectBitis spes_ES
dc.subjectAntivenomes_ES
dc.subjectHemorrhagees_ES
dc.subjectLethalityes_ES
dc.subjectCoagulant activityes_ES
dc.subjectSnake venomes_ES
dc.titlePreclinical assessment of the efficacy of a new antivenom (EchiTAb-Plus-ICP) for the treatment of viper envenoming in sub-Saharan Africaes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.typeArtículo científicoes_ES
dc.identifier.doi10.1016/j.toxicon.2009.08.010
dc.description.procedenceUCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias de la Salud::Instituto Clodomiro Picado (ICP)es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record